Navigation Links
Mental Disorders Drugs Market - New Industry Research Report Is Now Available for Pre-Order at Transparency Market Research
Date:8/23/2013

Albany, New York (PRWEB) August 23, 2013

A mental disorder is a psychological anomaly that is reflected in the behavior of the patient through distress, disability or any conduct that is not a part of a person’s normal mental development. The causes of mental disorders are varied in nature and many are also unclear. Psychiatric medication and psychotherapy are the two modes of treatment for mental disorder. In psychiatric medication drug classes such as antidepressants, anxiolytics, and antipsychotics are most commonly used.

Browse the report with Request TOC at http://www.transparencymarketresearch.com/mental-disorders-drugs.html.

Improvement in patient security policy, growth in domestic and foreign investment in the field of mental medication, and increase in the prevalence and the related awareness about mental health are the major drivers for the global mental disorders drugs market. However, skepticism about social pressure regarding mental diseases and their treatment, especially in less advanced countries, and the lack of government initiatives in such locations may hold back the growth of this market.

The overall mental disorders drugs market can be classified on the basis of the mental drugs such as antidepressants, antipsychotics, anxiolytics, drugs for schizophrenia, drugs for childhood and adolescent mental illness, and drugs for the treatment of substance and alcohol addiction, bipolar disease drugs, and others.

North America is the largest market for mental disorders drugs. Factors such as increasing government initiatives, better reimbursement policies, and general awareness about mental health and treatment are responsible for the growth of this market in this region. An increase in the awareness about the efficacy of mental disorders’ drugs and growth in the related clinical evidence will assist in the rapid growth of this market in Asia-Pacific. The major players in the mental disorders drugs market include pharmaceutical manufacturers such as Eli Lilly, AstraZeneca, Pfizer, Johnson and Johnson, GlaxoSmithKline, and Bristol-Myers Squibb.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
North America
Asia Pacific
Europe
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a technological growth map over time to understand the industry growth rate
It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments

Browse all Market Research reports: http://www.transparencymarketresearch.com

Read the full story at http://www.prweb.com/releases/2013/8/prweb11056047.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Mental Illness Tied to Higher Rates of Physical Problems: Report
3. Researchers ID Genes That May Determine Mental Illness
4. First contact: Early intervention key in diagnosis and treatment of serious mental illness
5. Media Multitasking Might Have Mental Upside
6. Experimental Pill for Multiple Sclerosis Shows Promise
7. Experimental Gel May Help Those With Advanced Parkinsons
8. Talking to Yourself Could Have Mental Benefits
9. Experimental Drug Eases Autistic Behaviors in Mice
10. Understanding and promoting mental health - Insights from psychological science
11. Developmental Woes Common in Siblings of Children With Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: